Honors & Awards

  • FDA-AACR Oncology Educational Fellow, American Association for Cancer Research (2024 - 2025)
  • Research Training Award for Fellows, American Society of Hematoloy (2024 - 2025)
  • Lymphoma Scientific Research Mentorship Program Errol Cook Memorial Scholar, Lymphoma Research Foundation (2024 - 2026)
  • Abstract Achievement Award, American Society of Hematology (2024)
  • Abstract Achievement Award, American Society of Hematology (2023)
  • HONORS Award, American Society of Hematology (2020)
  • Innovative Oncology Research Travel Award, Emory University (2017)
  • Abstract Achievement Award, American Society of Hematology (2017)

Professional Education

  • Master of Science, Emory University (2018)
  • Doctor of Medicine, Cornell University (2018)
  • Doctor of Medicine, Emory University (2018)
  • Master of Science, Cornell University (2018)
  • Doctor of Medicine, School Undefined 2, Medicine (2018)
  • Bachelor of Science, Cornell University, Biometry and Statistics (2013)
  • Master of Science, Emory University, Clinical Research (2018)
  • Board Certification, American Board of Internal Medicine, Hematology (2024)
  • Fellowship, Stanford University, Hematology and Medical Oncology (2024)
  • Residency, NYP-Weill Cornell Medical Center, Internal Medicine (2021)
  • MS, Emory University, Clinical Research (2018)
  • MD, Emory University (2018)

Stanford Advisors

Contact

  • Academic
    jsg1221@stanford.edu
    University - Scholar Department: School of Medicine Position: Medical Fellow

Additional Info

  • Mail Code: 5151

All Publications

  • Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy. Blood cancer discovery Goldstein, J. S., Phillips, N. A., Alizadeh, A. A. 2025: OF1-OF4

    Abstract

    In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development. See related article by Pomeroy and Palmer, p. XX.

    View details for DOI 10.1158/2643-3230.BCD-25-0071

    View details for PubMedID 40232087

  • Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma Goldstein, J. S., Scherer, F., Sworder, B. J., Diehn, M., Kurtz, D., Alizadeh, A. A. ELSEVIER. 2024: 4357-4358

    View details for DOI 10.1182/blood-2024-209735

    View details for Web of Science ID 001412802400042

  • The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL Kambhampati, S., Goldstein, J. S., Buller, S., Roschewski, M., Alizadeh, A. A., Thiruvengadam, N. ELSEVIER. 2024: 2276-2277

    View details for DOI 10.1182/blood-2024-203873

    View details for Web of Science ID 001412639100005

  • Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling Rossi, C., Boegeholz, J., Goldstein, J. S., Shi, S., Su, S., Tessoulin, B., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, X., Tian, F., Kurtz, D., Sugio, T., Noordenbos, T., Andre, M., Fornecker, L., Julia, E., Traverse-Glehen, A., Casasnovas, O., Binkley, M. S., Diehn, M., Ghesquieres, H., Alizadeh, A. A. ELSEVIER. 2024: 853-854

    View details for DOI 10.1182/blood-2024-201644

    View details for Web of Science ID 001412608600046

  • ViPOR's Venom - Rationally Targeting DLBCL with Precision. The New England journal of medicine Goldstein, J. S., Alizadeh, A. A. 2024; 390 (23): 2209-2211

    View details for DOI 10.1056/NEJMe2405437

    View details for PubMedID 38899699

  • Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC) Isbell, J. M., Goldstein, J., Hamilton, E. G., Liu, S., Eichholz, J., Buonocore, D. J., Rusch, V. W., Bott, M., Molena, D., Rocco, G., Yang, S., Rudin, C. M., Jones, D. R., Roff, A., Schultz, A., Chabon, J. J., Kurtz, D., Alizadeh, A. A., Li, B. T., Diehn, M. LIPPINCOTT WILLIAMS & WILKINS. 2024

    View details for Web of Science ID 001275557401867

  • Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy Goldstein, J., Kim, W., Yoon, S., Kim, S., Roschewski, M., Westin, J., Lynch, R. C., Alig, S. K., Close, S., Chabon, J. J., Rossi, D., Wilson, W. H., Diehn, M., Alizadeh, A. A., Kurtz, D. M. AMER SOC HEMATOLOGY. 2023

    View details for DOI 10.1182/blood-2023-187759

    View details for Web of Science ID 001159306700188

  • Novel agents in relapsed/refractory diffuse large B-cell lymphoma. Hematological oncology Varma, G., Goldstein, J., Advani, R. H. 2023; 41 Suppl 1: 92-106

    Abstract

    Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies. Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.

    View details for DOI 10.1002/hon.3143

    View details for PubMedID 37294966